comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 00:52:28 - browse：44

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Deliver public health messages at the right time

focus

WSS

Most antidepressants don't work on kids, teens, study finds

Histogen: Failed biotech offers rare public look inside

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Bill would stop addiction treatment from triggering child abuse inquiry

The future of health care in the House

Colorectal cancer study finds potential in overlooked immune cell

focus

comprehensive

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

3 questions for the future of Biden's cancer moonshot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

When women are denied an abortion, their children fare worse than peers

Alkermes shareholders re

How a small hospital in rural Puerto Rico survived Hurricane Maria

BioMarin wins approval for gene therapy to treat hemophilia A

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

After affirmative action ruling, medical educators look to 'holistic review'

Bristol 'take

hotspot

As billionaires fund anti

Chemotherapy drug shortage eases slightly but still widespread

The future of health care in the House

PBM executives asked to testify by House panel

How a small hospital in rural Puerto Rico survived Hurricane Maria

Primary care doctor shortage won't be solved by free med school tuition

focus

focus

focus

focus